Review




Structured Review

STEMCELL Technologies Inc easysep cd34 selection kit
Analysis of total synovium-derived cell population with four-color flow cytometry: representative sample . Cells are stained with 7-aminoactinomycin (7-AAD), CD45- fluoro-isothiocyanate (FITC), one phycoerythrin (PE)-conjugated antibody and one allophycocyanin (APC)-conjugated antibody or their isotypes. (a) Dye exclusion of debris and dead cells in forward scatter (FSC)/FL3 in contour plot (top) and dot plot (bottom). G1 gates for live cells. (b) Subgating of CD45-negative stromal (G2) and CD45-positive (G3) hematopoietic cell populations based on isotype staining with IgG1-FITC and cell granularity (side scatter). (c) Quantification of <t>CD34-expression</t> and CD90-expression within the stromal fraction. The gating for CD90-positive cells was based on IgG1-PE specifically measured on CD45-negative cells. (d) Quantification of CD14, CD3, and CD20-expression within G3. The gating for CD20-positive cells was performed on IgG1-PE measured on total cells. (e) Plots showing CD105-APC, CD73-PE, CD146-PE, and human leucocyte antigen (HLA)-DR-PE staining in the stromal fraction with their appropriate isotype controls.
Easysep Cd34 Selection Kit, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd34++fraction/pmc02875643-142-9-17?v=STEMCELL+Technologies+Inc
Average 90 stars, based on 1 article reviews
easysep cd34 selection kit - by Bioz Stars, 2026-07
90/100 stars

Images

1) Product Images from "Flow cytometric characterization of freshly isolated and culture expanded human synovial cell populations in patients with chronic arthritis"

Article Title: Flow cytometric characterization of freshly isolated and culture expanded human synovial cell populations in patients with chronic arthritis

Journal: Arthritis Research & Therapy

doi: 10.1186/ar2916

Analysis of total synovium-derived cell population with four-color flow cytometry: representative sample . Cells are stained with 7-aminoactinomycin (7-AAD), CD45- fluoro-isothiocyanate (FITC), one phycoerythrin (PE)-conjugated antibody and one allophycocyanin (APC)-conjugated antibody or their isotypes. (a) Dye exclusion of debris and dead cells in forward scatter (FSC)/FL3 in contour plot (top) and dot plot (bottom). G1 gates for live cells. (b) Subgating of CD45-negative stromal (G2) and CD45-positive (G3) hematopoietic cell populations based on isotype staining with IgG1-FITC and cell granularity (side scatter). (c) Quantification of CD34-expression and CD90-expression within the stromal fraction. The gating for CD90-positive cells was based on IgG1-PE specifically measured on CD45-negative cells. (d) Quantification of CD14, CD3, and CD20-expression within G3. The gating for CD20-positive cells was performed on IgG1-PE measured on total cells. (e) Plots showing CD105-APC, CD73-PE, CD146-PE, and human leucocyte antigen (HLA)-DR-PE staining in the stromal fraction with their appropriate isotype controls.
Figure Legend Snippet: Analysis of total synovium-derived cell population with four-color flow cytometry: representative sample . Cells are stained with 7-aminoactinomycin (7-AAD), CD45- fluoro-isothiocyanate (FITC), one phycoerythrin (PE)-conjugated antibody and one allophycocyanin (APC)-conjugated antibody or their isotypes. (a) Dye exclusion of debris and dead cells in forward scatter (FSC)/FL3 in contour plot (top) and dot plot (bottom). G1 gates for live cells. (b) Subgating of CD45-negative stromal (G2) and CD45-positive (G3) hematopoietic cell populations based on isotype staining with IgG1-FITC and cell granularity (side scatter). (c) Quantification of CD34-expression and CD90-expression within the stromal fraction. The gating for CD90-positive cells was based on IgG1-PE specifically measured on CD45-negative cells. (d) Quantification of CD14, CD3, and CD20-expression within G3. The gating for CD20-positive cells was performed on IgG1-PE measured on total cells. (e) Plots showing CD105-APC, CD73-PE, CD146-PE, and human leucocyte antigen (HLA)-DR-PE staining in the stromal fraction with their appropriate isotype controls.

Techniques Used: Derivative Assay, Flow Cytometry, Staining, Expressing

Influence of the isolation procedure on the detection of stromal markers . (a) Dot plot showing CD34- allophycocyanin (APC) and isotype staining of viable CD45-positive CD34-enriched cord blood mononuclear cells (CB-MNCs) before and after exposure to the digestion method. (b) Plots showing (top panel) human leucocyte antigen (HLA)-DR- phycoerythrin (PE) staining and (lower panel) forward scatter (FSC)/side scatter (SSC) of viable, CD45-positive peripheral blood mononuclear cells (PBMCs) before and after exposure to the digestion method. (c) Dot plots showing CD73-PE, CD105- fluoro-isothiocyanate (FITC) and isotype stainings of cultured passage five synovium-derived mesenchymal stem cells. (d) Plots showing CD146-PE and isotype staining in viable (negative for 7-aminoactinomycin (7-AAD) in peridinin chlorophyll protein channel) human osteosarcoma cells before and after exposure to the digestion method.
Figure Legend Snippet: Influence of the isolation procedure on the detection of stromal markers . (a) Dot plot showing CD34- allophycocyanin (APC) and isotype staining of viable CD45-positive CD34-enriched cord blood mononuclear cells (CB-MNCs) before and after exposure to the digestion method. (b) Plots showing (top panel) human leucocyte antigen (HLA)-DR- phycoerythrin (PE) staining and (lower panel) forward scatter (FSC)/side scatter (SSC) of viable, CD45-positive peripheral blood mononuclear cells (PBMCs) before and after exposure to the digestion method. (c) Dot plots showing CD73-PE, CD105- fluoro-isothiocyanate (FITC) and isotype stainings of cultured passage five synovium-derived mesenchymal stem cells. (d) Plots showing CD146-PE and isotype staining in viable (negative for 7-aminoactinomycin (7-AAD) in peridinin chlorophyll protein channel) human osteosarcoma cells before and after exposure to the digestion method.

Techniques Used: Isolation, Staining, Cell Culture, Derivative Assay

Quantification of surface marker expression in synovial digests
Figure Legend Snippet: Quantification of surface marker expression in synovial digests

Techniques Used: Marker, Expressing

Semi-quantitative assessment of vascularization in synovial tissue by immunohistochemistry . Magnification 100×. (a to c) von Willebrand Factor staining. (a) Positive endothelial cells are detected. (b) Isotype control. (c) Positive (sub)endothelial cells and fibroblasts are detected. (d to f) CD34 staining. (e) Isotype control. (c and f) Scores in different patient groups.
Figure Legend Snippet: Semi-quantitative assessment of vascularization in synovial tissue by immunohistochemistry . Magnification 100×. (a to c) von Willebrand Factor staining. (a) Positive endothelial cells are detected. (b) Isotype control. (c) Positive (sub)endothelial cells and fibroblasts are detected. (d to f) CD34 staining. (e) Isotype control. (c and f) Scores in different patient groups.

Techniques Used: Immunohistochemistry, Staining

Surface marker phenotype of cultured synovium-derived cells
Figure Legend Snippet: Surface marker phenotype of cultured synovium-derived cells

Techniques Used: Marker, Cell Culture

Detection and quantification of CD271 and CD34 in digests and cultured cells . (a) Plots of two representative samples. The CD45-negative fraction is gated in G1. Within this fraction, a portion of cells is positive for CD271 or CD34. Double positive cells are sometimes well clustered (lower plot). To be uniform, the quantification is performed using quadrant analysis. (b) Data points representing the expression levels in percentage positivity on the cell surface detected in the fresh digests. (c) Plots of cultured cells after staining. Cells are gated according to scatter properties (G1), viability (G2) and the signal for the markers is compared with the isotype controls. No double positive cells are recognized here. 7-AAD = 7-aminoactinomycin; APC = allophycocyanin; FITC = fluoro-isothiocyanate; FSC = forward scatter; PE = phycoerythrin; SSC = side scatter.
Figure Legend Snippet: Detection and quantification of CD271 and CD34 in digests and cultured cells . (a) Plots of two representative samples. The CD45-negative fraction is gated in G1. Within this fraction, a portion of cells is positive for CD271 or CD34. Double positive cells are sometimes well clustered (lower plot). To be uniform, the quantification is performed using quadrant analysis. (b) Data points representing the expression levels in percentage positivity on the cell surface detected in the fresh digests. (c) Plots of cultured cells after staining. Cells are gated according to scatter properties (G1), viability (G2) and the signal for the markers is compared with the isotype controls. No double positive cells are recognized here. 7-AAD = 7-aminoactinomycin; APC = allophycocyanin; FITC = fluoro-isothiocyanate; FSC = forward scatter; PE = phycoerythrin; SSC = side scatter.

Techniques Used: Cell Culture, Expressing, Staining

Comparing marker expression in the digests and cultures from the same samples
Figure Legend Snippet: Comparing marker expression in the digests and cultures from the same samples

Techniques Used: Marker, Expressing, Cell Culture



Similar Products

96
Miltenyi Biotec cd34 fraction
Cd34 Fraction, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd34++fraction/bio_rxiv__64898__2025__12__22__695871-246-1-6?v=Miltenyi+Biotec
Average 96 stars, based on 1 article reviews
cd34 fraction - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

99
Miltenyi Biotec cd34 cell fractions
Cd34 Cell Fractions, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd34++fraction/us12203096-489-17-31?v=Miltenyi+Biotec
Average 99 stars, based on 1 article reviews
cd34 cell fractions - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

99
Miltenyi Biotec cd34 cell fraction
Cd34 Cell Fraction, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd34++fraction/pm39277669-53-1-17?v=Miltenyi+Biotec
Average 99 stars, based on 1 article reviews
cd34 cell fraction - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

99
Qiagen cd34 cell fraction
Cd34 Cell Fraction, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd34++fraction/pmc11604037-358-7-18?v=Qiagen
Average 99 stars, based on 1 article reviews
cd34 cell fraction - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

90
Glaxo Smith autologous cd34+-enriched cell fraction strimvelis
FDA/EMA approved gene therapy product for rare monogenic diseases
Autologous Cd34+ Enriched Cell Fraction Strimvelis, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd34++fraction/pmc11222908-222-7-8?v=Glaxo+Smith
Average 90 stars, based on 1 article reviews
autologous cd34+-enriched cell fraction strimvelis - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


FDA/EMA approved gene therapy product for rare monogenic diseases

Journal: Clinical and Experimental Pediatrics

Article Title: Development of orphan drugs for rare diseases

doi: 10.3345/cep.2023.00535

Figure Lengend Snippet: FDA/EMA approved gene therapy product for rare monogenic diseases

Article Snippet: For instance, an autologous CD34+-enriched cell fraction, Strimvelis (GlaxoSmithKline plk, London, UK), which contains CD34+ cells transduced with a retroviral vector that encodes the human ADA cDNA sequence for ADA deficiency (introduced in 2016), and voretigene neparvovec-rzyl (Luxturna, Spark Therapeutics, Philadelphia, USA), for retinal dystrophy caused by mutations in the RPE65 gene, were approved by the FDA in 2017 at a cost of $850,000 per eye [ ].

Techniques: Plasmid Preparation, In Vivo, Ex Vivo, Mutagenesis, Modification, Variant Assay